亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!
已关闭
  • 文献求助详情
标题
Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy
领域 医学 内科学 肿瘤科 免疫疗法 遗传增强 多发性骨髓瘤 嵌合抗原受体 达拉图穆马 细胞因子释放综合征 临床研究 汽车T细胞治疗
网址
DOI
10.1182/blood-2019-126660 Doi
其它 期刊:Blood
作者:Jesus G. Berdeja; Melissa Alsina; Nina D. Shah; David S. Siegel; Sundar Jagannath; et al
出版日期:2020-02-14
求助人
shuofeng 在 2021-06-12 01:10:11 发布,悬赏 10 积分
下载
求助 / 应助时间线
  • 11天前,求助关闭

    YoviSun YoviSun 站长Lv11 关闭了本次求助。

    说明 求助违规(查看求助规则):该文献不存在全文(会议摘要、poster、视频等)【积分已退回】
  • 11天前

    研友852AxL 研友852AxL Lv12167 进行了留言

    Conclusions: The adverse events observed to date were manageable and consistent with known toxicities of CAR T therapies. Initial efficacy results with bb21217 CAR T therapy in heavily pretreated RRMM are encouraging, with 83% of patients demonstrating clinical response. Emerging data demonstrate long-term persistence of CAR T cells in long-term responders. Updated data to be presented will help determine whether treatment with bb21217 results in sustained CAR T cell persistence and durable clinical responses, and whether bb21217 is tolerated at higher doses.
  • 11天前

    研友852AxL 研友852AxL Lv12167 进行了留言

    For the 1 patient with G4 neurotoxicity, G3 CRS was also reported; both have resolved. A total of 18 patients were evaluable for response with ≥ 2 months of follow up or PD within 2 months. Fifteen (83%) patients demonstrated clinical response per IMWG criteria. Six of these subjects subsequently progressed. Nine patients remained in response, including 2 patients with ongoing response at months 15 and 18. MRD negative results at 10-5 nucleated cells or better were obtained by NGS in 10/10 evaluable responders at month 1. Overall, 6/8 patients evaluable at 6 months and 2/2 patients evaluable at 12 months had detectable CAR T cells in blood. Updated data from this study will be presented, including extended follow-up on the initial patients treated and early clinical and CAR T cell persistence data from at least 15 additional patients treated with up to 450 x 106 CAR+ T cells.
  • 11天前

    研友852AxL 研友852AxL Lv12167 进行了留言

    Results: Asof April 20, 2019, 22 patients (median age 63 [min;max 42 to 74]) have received bb21217 (12 at 150, 6 at 300 and 4 at 450). Eleven had high tumor burden, defined as ≥ 50% bone marrow plasma cells pre-infusion. Patients had a median of 7 (min;max 4 to 17) prior lines of therapy and 18/22 had prior autologous stem cell transplant; 7/22 had high-risk cytogenetics. Of the 22 patients, 19 received prior daratumumab, 13 received prior Bort/Len/Car/Pom/Dara. Median follow-up after bb21217 infusion was 23 weeks (<1 to 77 weeks). As of data cut-off, 13/22 patients developed cytokine release syndrome (CRS; 5 G1, 7 G2, 1 G3) and responded to supportive care, tocilizumab and/or corticosteroids. Five patients developed neurotoxicity [1 G1, 2 G2, 1 G3 (vertigo/dizziness), 1 G4 (encephalopathy, previously reported)].
  • 11天前

    研友852AxL 研友852AxL Lv12167 进行了留言

    Planned dose levels are 150, 450, 800, and 1,200 x 106 CAR+ T cells and intermediate dose levels are allowed. The primary outcome measure is incidence of adverse events (AEs), including dose-limiting toxicities (DLTs). Additional outcome measures are quality and duration of clinical response assessed according to the IMWG Uniform Response Criteria, evaluation of minimal residual disease (MRD), progression-free and overall survival, and quantification of CAR+ T cells in blood.
  • 11天前

    研友852AxL 研友852AxL Lv12167 进行了留言

    Methods: CRB-402 (NCT03274219) is an ongoing, multi-center phase 1 dose escalation trial of bb21217 planning to enroll 74 patients with RRMM who received ≥ 3 prior regimens, including a proteasome inhibitor and an immuno-modulatory agent, or are double-refractory to both classes. During dose escalation, enrollment is restricted to patients with ≥ 50% BCMA expression by IHC on malignant plasma cells. Peripheral blood mononuclear cells are collected via leukapheresis and sent to a central facility for transduction, expansion and release testing prior to being returned to the site for infusion. Patients undergo lymphodepletion with fludarabine (30 mg/m2) and cyclophosphamide (300 mg/m2) daily for 3 days, then receive bb21217 as a single infusion.
  • 11天前

    研友852AxL 研友852AxL Lv12167 进行了留言

    Introduction: Chimeric antigen receptor (CAR) T cell therapy directed against B cell maturation antigen (BCMA) has shown promising results for the treatment of relapsed refractory multiple myeloma (RRMM) in several phase 1 studies. Persistence of CAR T cells post infusion may be one determinant of duration of response. bb21217 is a next-generation anti-BCMA CAR T cell therapy based on investigational therapy idecabtagene vicleucel (bb2121) (Friedman 2018, Hum Gene Ther 29:585) that uses the same lentiviral CAR T design as bb2121, but adds the phosphoinositide 3-kinase inhibitor bb007 during ex vivo culture to enrich the drug product for memory-like T cells. Evidence suggests that CAR T cells with this phenotype may be more persistent and more potent than unselected CAR T cells. CRB-402 is a first-in-human study of bb21217 in patients with RRMM designed to assess safety, pharmacokinetics, efficacy and duration of effect.
  • 11天前

    研友852AxL 研友852AxL Lv12167 进行了留言

    Blood (2019) 134 (Supplement_1): 927.
  • 12天前

    shuofeng shuofeng 求助人 Lv1 发起了本次求助

绑定科研通微信公众号,转发赠积分,查看
当前机器人应助时间:5.83 秒

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
宓天问关注了科研通微信公众号
12分钟前
Ying完成签到,获得积分10
12分钟前
李祺森完成签到 ,获得积分15
14分钟前
智迟完成签到 ,获得积分15
15分钟前
研友_Z5A685完成签到,获得积分25
23分钟前
颜从筠完成签到,获得积分25
23分钟前
周周完成签到,获得积分10
27分钟前
cutelad完成签到,获得积分20
35分钟前
hzauer完成签到,获得积分20
43分钟前
宇文完成签到 ,获得积分10
49分钟前
艾羏完成签到 ,获得积分10
51分钟前
59分钟前
薰x1n完成签到 ,获得积分10
1小时前
1小时前
1小时前
cutelad完成签到,获得积分20
1小时前
研友_n0kjPL完成签到,获得积分10
1小时前
有人完成签到,获得积分20
1小时前
张婧仪完成签到,获得积分20
1小时前
jasonwee完成签到,获得积分10
1小时前
魔王重楼发布了新的文献求助30
1小时前
魔王重楼完成签到,获得积分10
1小时前
张成明完成签到 ,获得积分25
1小时前
1小时前
kxg完成签到 ,获得积分20
1小时前
IXSOZN完成签到,获得积分20
1小时前
1小时前
lab发布了新的文献求助10
1小时前
持卿应助蒋语海采纳,获得10
1小时前
赫连邑完成签到,获得积分20
1小时前
jackyzfy应助赫连邑采纳,获得10
1小时前
1小时前
1小时前
久久琼殷应助科研通管家采纳,获得10
1小时前
持卿因举报求助违规成功,获得积分10
2小时前
jackyzfy因举报求助违规成功,获得积分10
2小时前
研友852AxL因举报求助违规成功,获得积分10
2小时前
2小时前
宗映波完成签到,获得积分10
2小时前
柏小霜完成签到 ,获得积分10
2小时前
高分求助中
A Revision of the Lower Jurassic Ichthyosaurs of Germany with Descriptions of Two New Species 1000
Ausgedehnte ferrocenfunktionalisierte Tricarbonylchromarenkomplexe 300
Performances optimales et utilisation du systeme a ejecteur en production de froid 300
The Routledge Handbook of Multimodal Analysis 300
Cinema and Soft Power: Configuring the National and Transnational in Geo-politics 260
A new species of Ichthyotringa from the El Doctor Formation (Cretaceous), Hidalgo, Mexico 200
Revisiting the actinopterygian preoperculum 200
热门求助领域 (近24小时)
医学 材料科学 化学 生物 内科学 化学工程 细胞生物学 纳米技术 癌症研究 计算机科学 催化作用 电化学 疾病 光电子学 心脏病学
热门帖子
关注 科研通微信公众号,转发送积分 158286
求助须知:如何正确求助?哪些是违规求助? 64788
关于积分的说明 166602
捐赠科研通 126680
什么是DOI,文献DOI怎么找? 81655
版权声明 58693
我的Sci-Hub怎么了?Sci-Hub网页常见问题解释 55821